When comparing with the placebo, Chiglitazar groups showed comparable good safety. In terms of potential side effects related to PPAR agonists, there was no significant body weight gain in the ...
Division of Pediatric Neurooncology, Hopp Children’s Cancer Center (KiTZ) Heidelberg, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. *Corresponding Author: ...